Redeye Initiates Coverage of Herantis Pharma
2021-05-18 11:35:00
Redeye initiates coverage of Herantis Pharma, a biotech developing drug candidates in the difficult area of Parkinson’s, an area with great potential to improve the standard of care. The case hinges on blockbuster potential in this expanding market, supported by experienced management, institutional ownership and a prospective licensing deal. While the share trades close to fair value, longer-term upside is compelling.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/